53065-23-9

Basic information

• Product Name: 2(3H)-Benzothiazolone,4-methoxy-,hydrazone(9CI)
• Synonyms: 2(3H)-Benzothiazolone,4-methoxy-,hydrazone(9CI)
• CAS NO: 53065-23-9
• Molecular Formula: C₈H₉N₃OS
• Molecular Weight: 195.24
• Product Categories: BENZOTHIAZOLE
• Mol File: 53065-23-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2(3H)-Benzothiazolone,4-methoxy-,hydrazone(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(3H)-Benzothiazolone,4-methoxy-,hydrazone(9CI)(53065-23-9)
• EPA Substance Registry System: 2(3H)-Benzothiazolone,4-methoxy-,hydrazone(9CI)(53065-23-9)

Safety Data

• Hazardous Substances Data: 53065-23-9(Hazardous Substances Data)

Usage

Structure

Hydrazone derivative of benzothiazolone with a methoxy group attached at the 4-position

Applications

Medicinal chemistry, pharmaceutical research, synthesis of new organic compounds with therapeutic properties, tool for studying biological systems, fluorescent probe or marker in biochemical assays and imaging techniques

Potential

Interesting chemical structure and potential biological activities

Further research

Needed to fully understand the properties and potential applications in various fields of science and technology

Upstream product

• 90-04-0 2-methoxy-phenylamine 
• 1516-37-6 1-(2-methoxyphenyl)thiourea 
• 5464-79-9 4-methoxy-1,3-benzothiazol-2-amine 

Relevant articles and documents

METHOD OF PRODUCING POLYMERIZABLE COMPOUND, AND SOLUTION OF POLYMERIZABLE COMPOUND

Disclosed is a method of producing a polymerizable compound that enables production of, in high yield, a polymerizable compound used for producing an optical film or the like. The disclosed method of producing a polymerizable compound comprises reacting a compound represented by formula (I) with a compound represented by formula (II) in an organic solvent in which a base having a pKa from 6.1 to 9.5 is present, so as to obtain a reaction solution containing a polymerizable compound represented by formula (III).

Novel Triapine Derivative Induces Copper-Dependent Cell Death in Hematopoietic Cancers

Triapine, an iron chelator that inhibits ribonucleotide reductase, has been evaluated in clinical trials for cancer treatment. Triapine in combination with other chemotherapeutic agents shows promising efficacy in certain hematologic malignancies; however, it is less effective against many advanced solid tumors, probably due to the unsatisfactory potency and pharmacokinetic properties. In this report, we developed a triapine derivative IC25 (10) with potent antitumor activity. 10 Preferentially inhibited the proliferation of hematopoietic cancers by inducing mitochondria reactive oxygen species production and mitochondrial dysfunction. Unlike triapine, 10 executed cytotoxic action in a copper-dependent manner. 10-Induced up-expression of thioredoxin-interacting protein resulted in decreased thioredoxin activity to permit c-Jun N-terminal kinase and p38 activation and ultimately led to the execution of the cell death program. Remarkedly, 10 showed good bioavailability and inhibited tumor growth in mouse xenograft models. Taken together, our study identifies compound 10 as a copper-dependent antitumor agent, which may be applied to the treatment of hematopoietic cancers.

Novel Piperine Derivatives with Antidiabetic Effect as PPAR-γ Agonists

Piperine is an alkaloid responsible for the pungency of black pepper. In this study, piperine isolated from Piper nigrum L. was hydrolyzed under basic condition to obtain piperic acid and was used as precursor to carry out the synthesis of twenty piperine derivatives containing benzothiazole moiety. All the benzothiazole derivatives were evaluated for their antidiabetic potential by OGT test followed by assessment of active derivatives on STZ-induced diabetic model. It was observed that nine of twenty novel piperine analogues (5b, 6a-h), showed significantly higher antidiabetic activity in comparison with rosiglitazone (standard). Furthermore, these active derivatives were evaluated for their action as PPAR-γ agonists demonstrating their mechanism of action. The effects on body weight, lipid peroxidation, and hepatotoxicity after administration with active derivatives were also studied to further establish these derivatives as lead molecules for treatment of diabetes with lesser side-effects.